Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved ...

"Several preclinical and translational data studies suggest potential causative effects on bone health. One study with GLP-1 ...

GLP-1 receptor agonists may reduce the likelihood of mortality and increase odds for transplant wait-listing for patients ...

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why ...

Lung cancer patients who take medications called GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes ...

Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study.

GLP-1 receptor agonists vs other second-line therapies were not associated with an increased thyroid cancer risk among patients with type 2 diabetes.

(HealthDay News) — Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, according to a study published online Aug. 27 in JAMA Surgery ...

Patients with heart failure using GLP-1 RAs have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year.

Patients who are overweight or obese may have a lower risk of developing cancer if they take GLP-1 receptor agonists, data suggest.